Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome

JAMA Neurology

Volumn 71, Issue 3, 2014, Pages 350-354

  Witting, Nanna ^a   Vissing, John ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; CHOLINESTERASE INHIBITOR; EPHEDRINE; SALBUTAMOL;

COLD LIMB; CONGENITAL MYASTHENIC SYNDROME; DISEASE COURSE; DOSE RESPONSE; DOWNSTREAM OF TYROSINE KINASE 7 CONGENITAL MYASTHENIC SYNDROME; DRUG DOSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; GENE MUTATION; GENOTYPE; HEADACHE; HEART ATRIUM FLUTTER; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; MUSCLE CRAMP; ONSET AGE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT;

HUMANS; MUSCLE PROTEINS; MYASTHENIC SYNDROMES, CONGENITAL; TREATMENT OUTCOME;

EID: 84896768274     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.5590     Document Type: Review

References (22)

1. Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord. 2012; 22(2): 99-111.
2. Beeson D, Higuchi O, Palace J, et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science. 2006; 313(5795): 1975-1978.
3. Okada K, Inoue A, Okada M, et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science. 2006; 312(5781): 1802-1805.
4. Inoue A, Setoguchi K, Matsubara Y, et al. Dok-7 activates the muscle receptor kinase MuSK and shapes synapse formation. Sci Signal. 2009; 2(59): ra7. doi:10.1126/scisignal.2000113.
5. Hallock PT, Xu CF, Park TJ, Neubert TA, Curran T, Burden SJ. Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L. Genes Dev. 2010; 24(21): 2451-2461.
6. Cossins J, Liu WW, Belaya K, et al. The spectrum of mutations that underlie the neuromuscular junction synaptopathy in DOK7 congenital myasthenic syndrome. Hum Mol Genet. 2012; 21(17): 3765-3775.
7. Müller JS, Herczegfalvi A, Vilchez JJ, et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain. 2007; 130(pt 6): 1497-1506.
8. Palace J, Lashley D, Newsom-Davis J, et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain. 2007; 130(pt 6): 1507-1515.
9. Lynch GS, Ryall JG. Role of β-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev. 2008; 88(2): 729-767.
10. Ben Ammar A, Petit F, Alexandri N, et al. Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7. J Neurol. 2010; 257(5): 754-766.
11. Lashley D, Palace J, Jayawant S, Robb S, Beeson D. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology. 2010; 74(19): 1517-1523.
12. Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve. 2011; 44(5): 789-794.
13. Schara U, Barisic N, Deschauer M, et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord. 2009; 19(12): 828-832.
14. Mihaylova V, Scola RH, Gervini B, et al. Molecular characterisation of congenital myasthenic syndromes in Southern Brazil. J Neurol Neurosurg Psychiatry. 2010; 81(9): 973-977.
15. Lorenzoni PJ, Scola RH, Kay CS, et al. Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation. J Neurol Sci. 2013; 331(1-2): 155-157.
16. Selcen D, Milone M, Shen XM, et al. Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Ann Neurol. 2008; 64(1): 71-87.
17. Kinali M, Beeson D, Pitt MC, et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol. 2008; 201-202: 6-12.
18. Srour M, Bolduc V, Guergueltcheva V, et al. DOK7 mutations presenting as a proximal myopathy in French Canadians. Neuromuscul Disord. 2010; 20(7): 453-457.
19. Anderson JA, Ng JJ, Bowe C, et al. Variable phenotypes associated with mutations in DOK7. Muscle Nerve. 2008; 37(4): 448-456.
20. Burke G, Hiscock A, Klein A, et al. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord. 2013; 23(2): 170-175.
21. Mahjneh I, Lochmüller H, Muntoni F, Abicht A. DOK7 limb-girdle myasthenic syndrome mimicking congenital muscular dystrophy. Neuromuscul Disord. 2013; 23(1): 36-42.
22. Klein A, Pitt MC, McHugh JC, et al. DOK7 congenital myasthenic syndrome in childhood: early diagnostic clues in 23 children. Neuromuscul Disord. 2013; 23(11): 883-891.